Jiangsu Nhwa Pharmaceutical Co., LTD produces and sells central nervous system drugs, and cardiovascular and cerebrovascular drugs in China and internationally. The company offers drugs in the anesthesia, psychiatry, and neurological categories. It also provides APIs in the areas of central nervous system, anesthetic and sedative, and others. The company was founded in 1978 and is headquartered in Xuzhou, China.
Оборотен капитал
2022
2021
2020
2019
2018
2017
Парични средства и инвестиции
1532.21
1607.59
1402.42
1820.81
971.85
789.91
Приемници
0.00
0.00
0.00
0.00
0.00
0.00
Инвентарна книга
716.34
604.33
433.86
345.48
410.49
361.83
Други
12.59
15.14
5.71
92.09
1529.14
1106.18
Общо текущи активи
4650.40
4043.18
3319.58
3003.45
2911.49
2257.93
Acc Payable
255.74
267.17
165.19
127.55
352.77
330.03
Краткосрочен дълг
50.63
63.01
38.00
38.00
317.33
232.17
Други текущи пасиви
487.57
351.77
371.75
350.37
218.99
87.61
Текущи пасиви
793.94
681.96
574.95
515.92
983.62
742.08
Капиталова структура
Всички числа в милиони
Общо активи
482,86 щ.д.
Общо задължения
357124397,52 щ.д.
Дългосрочен дълг
4,43 щ.д.
Парични средства и екви
63049880,82 щ.д.
Goodwill
0,00 щ.д.
Неразпределена печалба
11865974,80 щ.д.
Обикновени акции
1007,59 щ.д.
Стойност на предприятието
28,37 щ.д.
Дивиденти за маса
Години
Q1
Q2
Q3
Q4
Общо
2009
0.000
0.014
0.000
0.000
0.014
2010
0.000
0.010
0.000
0.000
0.010
2011
0.000
0.013
0.000
0.000
0.013
2012
0.000
0.013
0.000
0.000
0.013
2013
0.000
0.021
0.000
0.000
0.021
2014
0.000
0.018
0.000
0.000
0.018
2015
0.000
0.024
0.000
0.000
0.024
2016
0.000
0.029
0.000
0.000
0.029
2017
0.000
0.037
0.000
0.000
0.037
2018
0.000
0.050
0.000
0.000
0.050
2019
0.000
0.060
0.000
0.000
0.060
2020
0.000
0.100
0.000
0.000
0.100
2021
0.000
0.100
0.000
0.000
0.100
2022
0.000
0.200
0.000
0.000
0.200
2023
0.000
0.200
0.000
0.000
0.200
Подобни запаси
Може да се интересувате и от
PILL.CN
Canntab Therapeutics Limited.
0.015 CAD
CNQ
CRON
Cronos Group Inc..
1.75 USD
NASDAQ
RMTI
Rockwell Medical, Inc..
3.71 USD
NASDAQ
ATNX
Athenex, Inc..
0.2031 USD
NASDAQ
SCYX
SCYNEXIS, Inc..
2.62 USD
NASDAQ
RDHL
RedHill Biopharma Ltd..
2.2 USD
NASDAQ
CPIX
Cumberland Pharmaceuticals Inc..
1.61 USD
NASDAQ
PRPH
ProPhase Labs, Inc..
9.15 USD
NASDAQ
OGI
OrganiGram Holdings Inc..
0.39 USD
NASDAQ
BOI.PA
Boiron SA.
37.15 EUR
EURONEXT
Frequently Asked Question
Why is your stock tool better than competitors?
Numfin provides most features for free and gives you accurate and expert data about public companies. We also offer unique features like AI copilot that are not found on other platforms
Can I trust the data on your website and where do they come from?
Absolutely. We receive the data from our partners and other official sources, such as popular stock exchanges (NASDAQ, NYSE, and others), SEC.gov, and other official platforms. Our data provider, FinancialModeling, also provides information for portals like Moody's, Harvard, Chevron, and others. All this proves the accuracy and authority of the information.
Who creates the content on your website and is it approved by experts in finance and investing?
All financial data is received from our data provider and then verified by industry experts. Additionally, we use various AI tools like ChatGPT to present content in a user-friendly and well-structured manner.
What problem does your tool solve? Who is the target audience for your tool
Our main goal is to present accurate and expert information about public companies in a structured manner. We work with investors and financial professionals who have a long-term outlook. Our community consists of private investors, business owners, stock analysts, fund managers, and people who are interested in investing.
Why did you decide to create your tool?
While managing our own money, we searched for the best analytical tool to help us better analyze public companies. Most websites that provided analytics for professional investors were expensive, and the cheap tools were either limited in functionality or lacked valuable company data. Even worse, some of them presented incorrect numbers. As a result, we combined our experience in business, IT, and finance to create the most affordable and useful solution for investors and anyone interested in finance and stock analysis.
What is the difference between free and paid options? Should I buy Pro version from start or it's ok to have a free version?
Most features on our website are free so that many people can use it to analyze companies on the world's top stock exchanges. However, some features, such as our artificial intelligence chat, advanced analytics, filters, and storing of vast historical data, require additional servers from our end. Therefore, we rely on your support to keep this amazing project running. If you would like to experience the full potential of our service, we strongly recommend that you purchase the PRO version, which comes with a 30-day money-back guarantee
Who is your team and do they have enough experience?
You can read about our team here, or you can contact us at [email protected] for more information.
